Artigos

Deus Ex Machina vence no TRF-2 disputa por marca

Deus Ex Machina vence no TRF-2 disputa por marca

Segundo relator, a inserção de “Brasil” não garante distintividade suficiente à marca.

Anvisa não pode estabelecer normas para propaganda de medicamentos

Anvisa não pode estabelecer normas para propaganda de medicamentos

Recentemente, a 1ª Turma do Superior Tribunal de Justiça (STJ) determinou que a Agência Nacional de Vigilância Sanitária (Anvisa) não possui o poder legal para impor restrições à propaganda de medicamentos. De acordo com o tribunal, a agência reguladora não tem a autoridade para criar normas que excedam as disposições da Lei 9.294/1996, que regula a propaganda de remédios e outros produtos.

Brazilian Superior Court of Justice (STJ) ruled that Brazilian Food/Health Authority (ANVISA) cannot establish rules for pharma advertising

Brazilian Superior Court of Justice (STJ) ruled that Brazilian Food/Health Authority (ANVISA) cannot establish rules for pharma advertising

On August 13, 2024, the First Panel of the STJ (Superior Court of Justice) ruled that ANVISA – National Health Surveillance Agency – does not have the legal authority to impose restrictions on drug advertising. According to the Court, the regulatory agency lacks the authority to create rules that exceed the provisions of Law 9.294/1996, which regulates the advertising of pharma and related products.

Brazilian Patent and Trademark Office "INPI" secures injunction to remove "fake services website" from the internet

Brazilian Patent and Trademark Office "INPI" secures injunction to remove "fake services website" from the internet

The Brazilian Patent and Trademark Office "INPI" obtained an injunction from the 6th Federal Court of Campinas - São Paulo State against a local company to remove the website https://portalinpi.com.br, which is very similar to the official INPI website, https://inpi.gov.br. The injunction also requires the company to cease using the INPI acronym and logo on its physical or virtual advertising platforms, including websites and social media.

Marketing de emboscada nas Olimpíadas: lições e desafios

Marketing de emboscada nas Olimpíadas: lições e desafios

O marketing de emboscada nas Olimpíadas levanta um debate complexo sobre inovação, ética e os limites do marketing.

Entenda quem pode usar marcas e logos da Olimpíada e patrocinadores

Entenda quem pode usar marcas e logos da Olimpíada e patrocinadores

Atletas, estádios, agências de viagem e empresas que vendem ingressos precisam ficar atentas ao regulamento do evento e às leis de propriedade intelectual.

Combating illegal Cell Phones: Striking a Balance Between Regulation and Market Freedom

Combating illegal Cell Phones: Striking a Balance Between Regulation and Market Freedom

Over the last few years, the spread of counterfeit goods on online sales platforms has become a noteworthy concern for Intellectual Property (“IP”) owners, manufacturers, consumers, and regulatory authorities.

Claming belonging: Strategies for managing imposter syndrome in the legal profession

Claming belonging: Strategies for managing imposter syndrome in the legal profession

Imposter Syndrome has been defined as “the persistent inability to believe that one’s success is deserved or has been legitimately achieved as a result of one’s own efforts or skills.” Generally, this means feeling not good enough or deserving enough in or for your role – thinking of yourself as a fraud.

A proteção da propriedade intelectual como estratégia internacional

A proteção da propriedade intelectual como estratégia internacional

No primeiro trimestre de 2024, o comércio entre Brasil e Estados Unidos alcançou a marca impressionante de US$ 18,8 bilhões, segundo dados divulgados recentemente pela Amcham Brasil, uma das maiores entidades multissetorial do país e uma das mais importantes.

Pharma Innovators and Generics in Brazil

Pharma Innovators and Generics in Brazil. The legal and case law environment

Within the industrial property discussion environment, more specifically with regard to innovation and technology protection through patents, companies that manufacture generics and similar drugs for many years were considered rivals to pharmaceutical laboratories holding patents. They were often nicknamed the “copy industry”, despite the fact that generic manufacturing is a legal and regulated activity.

Subcategorias

IDIOMA / LANGUAGE